25D-NBOMe, also known as NBOMe-2C-D, stems from the phenethylamine-derived hallucinogen 2C-D. Functioning similarly to its counterparts like 25I-NBOMe, this compound acts as a potent stimulator at the 5HT2A receptor. Since it emerged as a street drug in 2010, 25D-NBOMe has exhibited comparable impacts on human physiology, as observed with 25I-NBOMe and 25C-NBOMe. Due to concerns regarding its recreational utilization, the UK classified 25D-NBOMe as a Temporary Class Drug on June 10, 2013.

IUPAC name
CAS Number1354632-02-2
PubChem CID118536027
CompTox Dashboard (EPA)DTXSID601014189
Chemical and physical data
Molar mass315.413 g·mol−1

Toxicity and harm potential

The NBOMe compounds are frequently linked with life-threatening toxicity and fatalities. Scientific research on the NBOMe family has highlighted their neurotoxic and cardiotoxic nature. Individuals consuming NBOMe compounds often experience autonomic dysfunction, resulting in vasoconstriction, hypertension, tachycardia, and hallucinations. In addition, symptoms like agitation, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and even death have been reported.
One alarming trend is the misrepresentation of NBOMe and NBOHs as LSD on blotter papers, leading to accidental ingestion. These compounds’ bitter taste and distinctive safety profiles differentiate them from LSD. Despite the higher potency of NBOMes, LSD consumption at recreational doses has resulted in far fewer cases of acute toxicity. Fatalities associated with NBOMe intoxication often stem from individuals mistakenly believing they were ingesting LSD.
The long-term effects of NBOMe consumption remain largely unknown due to limited documentation. These compounds are typically not active orally and are administered sublingually, often causing tongue numbness and a metallic chemical taste. Some NBOMe compounds’ neurotoxic and cardiotoxic effects have been demonstrated in studies, indicating their potential harm to neuronal and cardiac health. Although no specific antidotes exist for NBOMes, acute intoxication is managed through symptomatic treatments and interventions such as benzodiazepines, antipsychotic drugs, and antiarrhythmic agents. Immediate attention to complications like rhabdomyolysis prevents critical outcomes such as metabolic acidosis and acute kidney injury.


25D-NBOMe was classified as a controlled substance in China as of October 2015.
In Sweden, Sveriges Riksdag designated 25D-NBOMe as a Schedule I narcotic, categorizing it under substances with no recognized medical use, effective from August 1, 2013. The Medical Products Agency published this regulation as LVFS 2013:15, specifying 25D-NBOMe as 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine.[29]
United Kingdom:
This substance is considered a Class A drug in the United Kingdom due to its inclusion in the N-benzyl phenethylamine clause outlined in the Misuse of Drugs Act 1971.
United States:
At the federal and state levels, 25D-NBOMe remains unregulated. However, its classification under the Federal Analog Act could be considered under certain circumstances, given its structural and functional resemblance to the controlled substance 2C-D.


1. What is 25D-NBOMe?

  • 25D-NBOMe is a derivative of the hallucinogenic compound 2C-D, belonging to the NBOMe family of drugs. It is known for its potent effects on the 5HT2A receptor, leading to hallucinogenic experiences.

2. What are the effects of 25D-NBOMe on the human body?

  • 25D-NBOMe is reported to induce effects similar to other compounds in the NBOMe family, including hallucinations, sympathomimetic toxicity (such as vasoconstriction, hypertension, and tachycardia), and autonomic dysfunction. It is important to note that consumption of this compound has been associated with life-threatening toxicity and fatalities.

3. How is 25D-NBOMe regulated in different countries?

  • 25D-NBOMe is a controlled substance in various countries, including China, Sweden, and the United Kingdom. In the United States, it remains unregulated at the federal and state levels, although it may be subject to specific regulations under the Federal Analog Act.

4. Are there any known long-term effects of 25D-NBOMe?

  • Due to limited documentation, the long-term effects of 25D-NBOMe consumption still need to be discovered. Researchers continue exploring its potential impacts on neuronal and cardiac health, but comprehensive data on its long-term effects must be available.

5. What should I do if I suspect someone has ingested 25D-NBOMe?

  • If you suspect someone has ingested 25D-NBOMe, it is crucial to seek immediate medical assistance. Given the potential for life-threatening complications, prompt medical intervention is essential. Inform medical professionals about the specific substance ingested to facilitate appropriate treatment.

6. How does 25D-NBOMe differ from other hallucinogens?

  • 25D-NBOMe is known for its structural and functional resemblance to other compounds, such as 2C-D and 25I-NBOMe. However, its unique effects and potential toxicities differentiate it from other commonly known hallucinogens, and it has garnered attention due to its vigorous agonist activity at various receptors.

7. What precautions should one take when handling 25D-NBOMe?

  • Handling 25D-NBOMe or any related substances should be done with extreme caution. Avoiding accidental ingestion, ensuring proper storage, and adhering to relevant legal regulations regarding its use and distribution are essential precautions to observe.

8. Can 25D-NBOMe be used for any medicinal purposes?

  • As of current knowledge, there are no recognized medical uses for 25D-NBOMe. Research into its potential therapeutic applications is limited, and its use is primarily associated with recreational purposes, often leading to serious health risks.


1. Anvisa (2023-07-24). “RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” [Collegiate Board Resolution No. 804 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.

2. Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). “Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists”. ACS Chemical Neuroscience. 5 (3): 243–9. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.

**3. Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.

4. Casale JF, Hays PA (2012). “Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues – Part I” (PDF). Microgram Journal. 9 (2): 84–109. Archived from the original (PDF) on 13 May 2017. Retrieved 14 January 2014.

5. “Temporary class drug order report on 5-6APB and NBOMe compounds”. UK Home Office. 4 Jun 2013. Retrieved 2013-07-10.

6. Sean I, Joe R, Jennifer S, and Shaun G (28 March 2022). “A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)”. Clinical Toxicology. 60 (8): 966–969. doi:10.1080/15563650.2022.2053150. PMID 35343858. S2CID 247764056.

7. Amy E, Katherine W, John R, Sonyoung K, Robert J, Aaron J (December 2018). “Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors”. Biochemical Pharmacology. 158: 27–34. doi:10.1016/j.bcp.2018.09.024. PMC 6298744. PMID 30261175.

8. Jolanta Z, Monika K, and Piotr A (26 February 2020). “NBOMes–Highly Potent and Toxic Alternatives of LSD”. Frontiers in Neuroscience. 14: 78. doi:10.3389/fnins.2020.00078. PMC 7054380. PMID 32174803.

9. Lipow M, Kaleem SZ, Espiridion E (30 March 2022). “NBOMe Toxicity and Fatalities: A Review of the Literature”. Transformative Medicine. 1 (1): 12–18. doi:10.54299/tmed/msot8578. ISSN 2831-8978. S2CID 247888583.

10. Micaela T, Sabrine B, Raffaella A, Giorgia C, Beatrice M, Tatiana B, Federica B, Giovanni S, Francesco B, Fabio G, Krystyna G, Matteo M (21 April 2022). “Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs”. Front Psychiatry. 13: 875722. doi:10.3389/fpsyt.2022.875722. PMC 9069068. PMID 35530025.

11. Cristina M, Matteo M, Nicholas P, Maria C, Micaela T, Raffaella A, Maria L (12 December 2019). “Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe”. Frontiers in Pharmacology. 10: 1406. doi:10.3389/fphar.2019.01406. PMC 6921684. PMID 31915427.

12. Anna R, Dino L, Julia R, Daniele B, Marius H, Matthias L (December 2015). “Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)”. Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099. S2CID 10382311.

13. David W, Roumen S, Andrew C, Paul D (6 February 2015). “Prevalence of use and acute toxicity associated with the use of NBOMe drugs”. Clinical Toxicology. 53 (2): 85–92. doi:10.3109/15563650.2015.1004179. PMID 25658166. S2CID 25752763.

14. Humston C, Miketic R, Moon K, Ma P, Tobias J (2017-06-05). “Toxic Leukoencephalopathy in a Teenager Caused by the Recreational Ingestion of 25I-NBOMe: A Case Report and Review of Literature”. Journal of Medical Cases. 8 (6): 174–179. doi:10.14740/jmc2811w. ISSN 1923-4163.

15. Justin P, Stephen R, Kylin A, Alphonse P, Michelle P (2015). “Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper”. Journal of Analytical Toxicology. 39 (8): 617–623. doi:10.1093/jat/bkv073. PMC 4570937. PMID 26378135.

16. Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, et al. (October 2017). “Death after 25C-NBOMe and 25H-NBOMe consumption”. Forensic Science International. 279: e1–e6. doi:10.1016/j.forsciint.2017.08.028. PMID 28893436.

17. Byard RW, Cox M, Stockham P (November 2016). “Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances”. Journal of Forensic Sciences. 61 (6): 1546–1548. doi:10.1111/1556-4029.13212. PMID 27723094. S2CID 4734566.

18. Sabastian LP, Christoffer B, Martin H, Martin AC, Jan K, Jesper LK (14 February 2014). “Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability”. Neurochemical Research. 39 (10): 2018–2023. doi:10.1007/s11064-014-1253-y. PMID 24519542. S2CID 254857910.

19. Adam H (18 January 2017). “Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens”. Neuropharmacology of New Psychoactive Substances. Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 283–311. doi:10.1007/7854_2016_64. ISBN 978-3-319-52444-3. PMID 28097528.

20. Boris D, Cristian C, Marcelo K, Edwar F, Bruce KC (August 2016). “Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS”. Journal of Chromatographic Science. 54 (7): 1153–1158. doi:10.1093/chromsci/bmw095. PMC 4941995. PMID 27406128.

21. Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, Eduardo C, Pierluigi S, Giovanni M, Guiseppe B, Fabrizio S (3 July 2014). “25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug”. BioMed Research International. 2014: 734749. doi:10.1155/2014/734749. PMC 4106087. PMID 25105138.

22. Adam JP, Simon HT, Simon LH (September 2021). “Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens”. Novel Psychoactive Substances: Classification, Pharmacology and Toxicology (2 ed.). Academic Press. pp. 279–300. doi:10.1016/B978-0-12-818788-3.00008-5. ISBN 978-0-12-818788-3. S2CID 240583877.

23. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (Dec 2000). “Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications”. Circulation. 102 (23): 2836–41. doi:10.1161/01.CIR.102.23.2836. PMID 11104741.

24. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (Jan 2000). “Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine”. Molecular Pharmacology. 57 (1): 75–81. PMID 10617681.

25. Roth BL (Jan 2007). “Drugs and valvular heart disease”. The New England Journal of Medicine. 356 (1): 6–9. doi:10.1056/NEJMp068265. PMID 17202450.

26. Xu P, Qiu Q, Li H, Yan S, Yang M, Naman CB, et al. (26 February 2019). “25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro”. Neuroto

Leave a Comment

Your email address will not be published. Required fields are marked *